Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The link above used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
(semaglutide injection 0.5 mg | 1 mg)
Click here for Ozempic® Prescribing Information
(insulin aspart injection 100 U/mL)
Click here for Fiasp® Prescribing Information
(liraglutide injection 1.2mg | 1.8mg)
Click here for Victoza® Prescribing Information
(insulin degludec injection 100 U/mL,
Click here for Tresiba® Prescribing Information
(insulin detemir [rDNA origin] injection)
Click here for Levemir® Prescribing Information
(insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection)
Click here for Xultophy® 100/3.6 Prescribing Information
(insulin aspart injection 100 Units/mL)
Click here for NovoLog® Prescribing Information
NovoLog® Mix 70/30
(insulin aspart protamine and insulin aspart injectable suspension 100 U/mL)
Click here for NovoLog® Mix 70/30 Prescribing Information
Click here for Prandin® Prescribing Information
(glucagon [rDNA origin] for injection)
More information about GlucaGen® HypoKit®
Click here for GlucaGen® HypoKit® Prescribing Information
© 2018 Novo Nordisk. All rights reserved. USA18DCP00047 January 2018